newsfilter
← Latest News
GlobeNewswire·

Aravive to Present Promising Updated Data from Phase 2 Trial of Batiraxcept in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma at ASCO 2023

HOUSTON, May 25, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV, "the Company")), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the